Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

University of Toronto

$70,000.00

The in vivo role of Polycomb-like 2 (Pcl2) in cell cycle control and tumour development

FY 2009-10

Summary
Normal development is tightly regulated by gene networks that control the fate pathways of embryonic stem cells (ESCs) - deciding if they will maintain their stem cell properties or differentiate into various tissues of the body. Disregulation of these networks has been associated with cancer development. While investigating this network, our lab has identified Polycomb-like 2 (Pcl2), a member of the Polycomb Group (PcG) of proteins. The PcG proteins have been shown to be important in maintaining ESCs and show a higher expression level in cancers such as lymphomas. Through work in mouse ESCs our lab has shown that Pcl2 is required for cells to differentiate. Pcl2 is known to interact with other proteins important in controlling cell cycle regulation. Changes in cell cycle progression have been linked to cancer progression. Pcl2 is expressed at its highest in the developing embryo, but is also present in adult tissues such as the bone marrow, spleen and thymus and stem cells that eventually become different kinds of red and white blood cells. To follow up to our analysis in mouse ESCs, we aim to study the role of Pcl2 in development and cancer progression using a mouse model. Our hypothesis is that Pcl2 is a tumour suppressor, and altering its level in the body will lead to tumour development. We will use mice that do not express Pcl2 protein and examine various organs at different ages to see what changes are caused by the lack of Pcl2. Preliminary work has shown these mice die prematurely of unknown causes, but many have early lymphoma symptoms. It is extremely important to investigate the role of Pcl2 at the whole animal level, so we may gain information about how Pcl2 works in normal development and its role in tumour formation and cancer progression. By discovering the role of new proteins in cancer development, these proteins might become new markers to help in diagnosing cancers or targets for new drug therapies.
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
206171
Name
Manias Janet L
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
The in vivo role of Polycomb-like 2 (Pcl2) in cell cycle control and tumour development
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$70,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Cancer; Cell Cycle; Gene Targeting; Hematopoetic Stem Cells; Histone Modification; In Vivo; Lymphoma; Murine Embryonic Stem Cell; Mutant Mouse Model; Polycomb-Like 2 Protein
Abstract
Normal development is tightly regulated by gene networks that control the fate pathways of embryonic stem cells (ESCs) - deciding if they will maintain their stem cell properties or differentiate into various tissues of the body. Disregulation of these networks has been associated with cancer development. While investigating this network, our lab has identified Polycomb-like 2 (Pcl2), a member of the Polycomb Group (PcG) of proteins. The PcG proteins have been shown to be important in maintaining ESCs and show a higher expression level in cancers such as lymphomas. Through work in mouse ESCs our lab has shown that Pcl2 is required for cells to differentiate. Pcl2 is known to interact with other proteins important in controlling cell cycle regulation. Changes in cell cycle progression have been linked to cancer progression. Pcl2 is expressed at its highest in the developing embryo, but is also present in adult tissues such as the bone marrow, spleen and thymus and stem cells that eventually become different kinds of red and white blood cells. To follow up to our analysis in mouse ESCs, we aim to study the role of Pcl2 in development and cancer progression using a mouse model. Our hypothesis is that Pcl2 is a tumour suppressor, and altering its level in the body will lead to tumour development. We will use mice that do not express Pcl2 protein and examine various organs at different ages to see what changes are caused by the lack of Pcl2. Preliminary work has shown these mice die prematurely of unknown causes, but many have early lymphoma symptoms. It is extremely important to investigate the role of Pcl2 at the whole animal level, so we may gain information about how Pcl2 works in normal development and its role in tumour formation and cancer progression. By discovering the role of new proteins in cancer development, these proteins might become new markers to help in diagnosing cancers or targets for new drug therapies.
Competitiondate
200910
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Manias, Janet L
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $70,000~ $0~